Lilly wins FDA approval for new drug to slow Alzheimer'sThe FDA cleared Eli Lilly's Alzheimer's treatment, offering competition to Eisai's drug at a slightly higher cost, emphasizing the potential cost advantage and convenience of Lilly's treatment.
EU regulator rejects Alzheimer's drug lecanemabThe European Medicines Agency (EMA) rejected a license for an Alzheimer's treatment due to serious side effects outweighing benefits.
Lilly wins FDA approval for new drug to slow Alzheimer'sThe FDA cleared Eli Lilly's Alzheimer's treatment, offering competition to Eisai's drug at a slightly higher cost, emphasizing the potential cost advantage and convenience of Lilly's treatment.
EU regulator rejects Alzheimer's drug lecanemabThe European Medicines Agency (EMA) rejected a license for an Alzheimer's treatment due to serious side effects outweighing benefits.
FDA approves new Alzheimer's treatment, donanemab from Eli LillyThe FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.
Researchers call for a major rethink of how Alzheimer's treatments are evaluatedLecanemab approved by FDA for Alzheimer's treatmentDisease-modifying drugs target root cause and offer cumulative benefits
FDA approves new Alzheimer's treatment, donanemab from Eli LillyThe FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.
Researchers call for a major rethink of how Alzheimer's treatments are evaluatedLecanemab approved by FDA for Alzheimer's treatmentDisease-modifying drugs target root cause and offer cumulative benefits
The Next Potential Alzheimer's Drug Clears a Big HurdleDrug companies are making progress in Alzheimer's treatment with FDA panel's positive evaluation of Eli Lilly's donanemab.